Sygnature Discovery Expands US Presence With New Office in San Francisco
Complete the form below to unlock access to ALL audio articles.
Sygnature Discovery, a world-leading integrated discovery and pre-clinical solutions provider, has established a new office presence in South San Francisco’s biotech hub at Oyster Point, where it can better serve current and future clients on the US west coast.
The new office presence comes in the wake of another year of impressive growth for the company, which has recently expanded operations at its headquarters in Nottingham, UK, as well as opening a second co-located integrated drug discovery site at the world-class research campus at Alderley Park, UK.
Sygnature established its first US office in 2019 in the heart of the Cambridge–Boston biotech hub in Massachusetts, and this expansion of its US presence with a second office will help meet growing demand from its US customers, which range from major pharma through to small seed-funded biotechs.
“Our very first client was actually from the US,” said Simon Hirst, Sygnature’s CEO and founder “and it remains a very significant market for us, both now and in our future strategy. It’s fantastic to have a base on the west coast, and in such a vibrant hub for the life sciences community.
“Our approach to drug discovery is based on true collaboration and partnership with our clients and having a physical presence near to many of them helps us to work the way we believe in, strengthening those ties and relationships that lead to success.”
The new office is located on Gateway Boulevard, Oyster Point, in South San Francisco – often nicknamed “the Birthplace of Biotechnology” and home to one of the largest biotech clusters in the world, with over 200 biotech companies, and 11.5 million square feet of biotech space across 500 acres.
Sygnature offers high-quality, fully-integrated drug discovery and pre-clinical services to customers around the world, as well as flexible, stand-alone solutions in medicinal chemistry, in vitro biology, computational chemistry, DMPK and pre-clinical experimental services.